Covovax trials begin in India, says Adar Poonawalla - Serum Institute targeting to launch vaccine by September
In August 2020, US-based vaccine maker Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.
"Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Poonawalla said in a tweet.
The development and commercialisation pact between Novavax and SII excludes major upper-middle and high-income countries, for which Novavax continues to retain rights.
In January this year, Poonawalla had said SII expected to launch Covovax by June 2021.
"Our partnership for a COVID-19 vaccine with @Novavax has also published excellent efficacy results. We have also applied to start trials in India. Hope to launch #COVOVAX by June 2021!", Poonawalla had said in a tweet.
SII is already supplying AstraZeneca/Oxford COVID-19 vaccine, Covishield, in India and to other countries across the world.
0 Response to " Covovax trials begin in India, says Adar Poonawalla - Serum Institute targeting to launch vaccine by September"
Post a Comment
Disclaimer Note:
The views expressed in the articles published here are solely those of the author and do not necessarily reflect the official policy, position, or perspective of Kalimpong News or KalimNews. Kalimpong News and KalimNews disclaim all liability for the published or posted articles, news, and information and assume no responsibility for the accuracy or validity of the content.
Kalimpong News is a non-profit online news platform managed by KalimNews and operated under the Kalimpong Press Club.
Comment Policy:
We encourage respectful and constructive discussions. Please ensure decency while commenting and register with your email ID to participate.
Note: only a member of this blog may post a comment.